What is BioHarvest Sciences's gross profit margin?

What were the key takeaways from BioHarvest Sciences’s earnings call?

What is the revenue and EPS growth rate for BioHarvest Sciences year over year?

What were the key takeaways from BioHarvest Sciences's earnings call?

What is BioHarvest Sciences's latest dividend and current dividend yield?

What does BioHarvest Sciences do and what are its main business segments?

What is the market's earnings forecast for BioHarvest Sciences next quarter?

What guidance did BioHarvest Sciences's management provide for the next earnings period?

- **Revenue Growth Accelerates**: Q3 2025 revenue up 39% YoY to $9.1M, driven by 722% CDMO surge and VINIA Inside expansion.
- **New Product Success**: VINIA BloodFlow Hydration launched to 75,000+ users, with early adopter feedback on taste and efficacy exceeding expectations.
- **Strategic Capital Raise**: $30.8M in funding secures liquidity for 2026 growth, including tripling manufacturing capacity.
- **CDMO Pipeline Strengthens**: 300+ active leads, with 4 deals in advanced stages and 25% ownership in Saffron Tech partnership.
- **Gross Margin Expansion**: 61% in Q3 2025, targeting 65%+ with scale and CDMO royalty-based margins >70%.
- **Breakeven Near**: Adjusted EBITDA loss of $0.4M in Q3, with Q4 2025 guidance for near breakeven and 2026 profitability.

**【CEO Opening Remarks】**
- Q3 2025 revenue grew 39% YoY to $9.1 million, with product revenue up 30% to $8.4 million and CDMO revenue surging 722% to $0.7 million.
- VINIA Inside strategy expanded with 75,000+ active users, driven by core capsules (88% of product revenue) and new products like VINIA 2X Formula Chews.
- CDMO partnership with Saffron Tech to develop high-value saffron compounds, with BioHarvest retaining 25% ownership.
- Launched VINIA BloodFlow Hydration in late November, targeting the $17B electrolyte market with a 90-day money-back guarantee.
- Gross margin improved to 61% due to scale and cost optimization.
- Secured $30.8M in capital via equity and debt conversions, reducing debt and warrant overhang.
- Q4 2025 guidance: $9-9.5M revenue, adjusted EBITDA near breakeven.

**【CFO Financial Commentary】**
- Q3 2025 GAAP net loss: $2.5M (-$0.14/share) vs. $2.7M (-$0.16/share) in Q3 2024.
- Adjusted EBITDA loss: $0.4M vs. $1.7M YoY, driven by cost control and revenue growth.
- Gross profit: $5.6M (61% of revenue) vs. $3.7M (57% of revenue) YoY.
- Operating expenses: $6.5M (+12% YoY) due to marketing and CDMO expansion.
- Cash balance: $11M as of Sep 30, 2025, plus $19.9M from recent equity raise.

**【Q&A Highlights】**
- **Hydration Product Ramp-Up**: VINIA BloodFlow Hydration launched to 75,000+ existing customers in late Nov, with broader rollout in Dec. Early adopter feedback on taste and efficacy is positive, with plans to expand to Amazon in early 2026.
- **Saffron Tech Partnership**: Running Stage 1 and 2 in parallel, targeting 9-month timeline to large-scale production. Potential to replicate VINIA's Resveratrol success with super-saffron.
- **CDMO Pipeline**: 300+ active leads, with 4 deals in advanced stages. Tate & Lyle partnership progressing with second plant sourcing.
- **Exosome Technology**: Medium-term opportunity for CDMO customers, with downstream process development for new manufacturing facility.
- **Health Pros Program**: Onboarded 75 professionals in Phase 1, targeting 300 by end-2025. Early conversion rates and commission structure (high-teens) are cost-effective alternatives to traditional marketing.
- **2026 Outlook**: CDMO revenue expected to grow >70% YoY, with long-term goal of 75%+ revenue from CDMO vs. 25% from DTC.


BHST

BHST fundamentals

You can ask Aime